sulperazone profile

sulperazone: combination of above two cpds [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	130312
SCHEMBL ID	1649819
MeSH ID	M0161826

Synonym
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)(4-hydroxyphenyl)acetyl)amino)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-(6alpha,7beta(r*)))-, mixt. with (2s-cis)-3,3-dimethyl-7-ox
sulperazone
92739-15-6
sulperazon
cefoperasone-sulbactam mixt.
bacamp
jincetam
cefactam
SCHEMBL1649819
(2s,5r)-3,3-dimethyl-4,4,7-trioxo-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(6r,7r)-7-[[2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo
(2s,5r)-3,3-dimethyl-4,4,7-trioxo-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(6r,7r)-7-[[(2r)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabi

Excerpt	Reference	Relevance
"Sulperazone is concluded to be a useful antibiotic for treating complicated UTI induced by beta-lactamase production organisms from the point of microbiology and safety."	( [Microorganisms isolated from urinary tract infection and their beta-lactamase production and evaluation of clinical efficacy of sulperazone]. Araki, T; Chigusa, I; Hayashi, N; Kawahara, S; Kawamura, J; Okabe, S; Saito, K; Suzuki, I; Suzuki, N; Takeno, K, 1988)	1.2

Excerpt	Reference	Relevance
" Mild or moderate side effect (allergic reaction including rash etc."	( [Efficacy and safety of sulbactam/cefoperazone for hepato-biliary infections]. Amako, Y; Fujisaki, M; Hirano, M; Ishii, J; Itakura, M; Iwasa, T; Kako, M; Koyama, M; Mitamura, K; Nakaya, S; Nishio, T; Ohswawa, N; Ohyama, R; Okuda, K; Oohira, S; Saito, H; Shinagawa, N; Sugiyama, A; Takashima, S; Takeda, S; Ueda, M; Yamada, M; Yasuda, Y; Zeze, F, 1997)	0.3

Excerpt	Reference	Relevance
" The method was successfully applied in a pharmacokinetic study of Sulperazon injection in six hospital-acquired pneumonia (HAP) patients."	( Liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of cefoperazone and sulbactam in plasma and its application to a pharmacokinetic study. Guo, B; Shi, Y; Wang, M; Yu, J; Zhang, J; Zhang, Y; Zhou, Y, 2010)	0.36

Excerpt	Reference	Relevance
"In the treatment of severe infections complicated to blood dyscrasia, the efficacy and usefulness of fosfomycin (FOM) in combination with sulbactam (SBT)/cefoperazone (CPZ) were compared between patients receiving FOM in the first followed by SBT/CPZ (Group A) and those receiving both drugs simultaneously (Group B)."	( [Clinical efficacy of fosfomycin in combination with sulbactam/cefoperazone in the treatment of severe infections complicated to blood dyscrasia. Working Group of Kanto Combination Therapy for FOM + SBT/CPZ]. Ann, E; Bessho, M; Dan, K; Egashira, M; Fukuda, M; Hirai, H; Hirasawa, A; Hirashima, K; Hoshino, T; Hosoya, N; Ikeda, Y; Karasawa, M; Kawai, N; Kitamura, K; Kizaki, M; Miura, Y; Miyazawa, K; Nagasu, M; Naruse, T; Noguchi, M; Ohmine, K; Oshimi, K; Sugai, M; Takagi, S; Toyama, K, 1998)	0.3

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (3.23)	18.7374
1990's	16 (51.61)	18.2507
2000's	10 (32.26)	29.6817
2010's	2 (6.45)	24.3611
2020's	2 (6.45)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	9 (28.13%)	5.53%
Reviews	2 (6.25%)	6.00%
Case Studies	2 (6.25%)	4.05%
Observational	0 (0.00%)	0.25%
Other	19 (59.38%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (10)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Single-dose, Two-way Crossover Study to Evaluate Bioequivalence of Two Formulations of Cefoperazone Sodium and Sulbactam Sodium Combination (1/1 g/Vial) After Intravenous Infusion of 1 g Cefoperazone Sodium and 1 g Sulbactam Sodium in Health [NCT05654090]	Phase 4	14 participants (Anticipated)	Interventional	2022-08-25	Active, not recruiting
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]	Early Phase 1	11 participants (Actual)	Interventional	2014-03-06	Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy [NCT04370145]	Phase 4	160 participants (Actual)	Interventional	2021-05-01	Completed
Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy in Biliary Atresia: a Randomized Controlled Trial [NCT05925309]		356 participants (Anticipated)	Interventional	2023-07-01	Recruiting
Epidemiological Study on Drug-induced Coagulation Disorder Caused by Cefoperazone Sulbactam Sodium and Construction of Prediction Model [NCT05535309]		8,000 participants (Anticipated)	Observational	2021-11-02	Active, not recruiting
Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections In Slovakia. An Open, Prospective, Non-Comparative Study. [NCT00463762]		0 participants (Actual)	Observational	2007-05-31	Withdrawn
Escalade or Deseacalade Antibiotic Use in Severe Acute Pancreatitis [NCT01992198]	Phase 4	60 participants (Anticipated)	Interventional	2012-07-31	Recruiting
Phase Ⅱ Study on Ceftazidime Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection [NCT01601093]	Phase 2	288 participants (Anticipated)	Interventional	2011-11-30	Suspended(stopped due to other project got priority)
A Randomized, Open Label, Multicentre Phase Iv Study To Evaluate The Efficacy And Safety Of Magnex (Cefoperazone-Sulbactam) In Comparison With Ceftazidime Plus Amikacin And Metronidazole In The Treatment Of Intra-Abdominal Infections [NCT00360607]	Phase 4	307 participants (Actual)	Interventional	2004-07-31	Completed
A Prospective, Randomized Clinical Trial to Treat Intra-abdominal Infection Preventively After Pancreatic Surgery Based on Serum Lactate Changes [NCT05052619]		297 participants (Anticipated)	Interventional	2021-07-01	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
methanol Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.	2.03	1	0	alkyl alcohol; one-carbon compound; primary alcohol; volatile organic compound	amphiprotic solvent; Escherichia coli metabolite; fuel; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite
ampicillin Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.	2.71	3	0	beta-lactam antibiotic; penicillin allergen; penicillin	antibacterial drug
vancomycin Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.	2.31	1	0	glycopeptide	antibacterial drug; antimicrobial agent; bacterial metabolite
amikacin Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.	2	1	0	alpha-D-glucoside; amino cyclitol glycoside; aminoglycoside; carboxamide	antibacterial drug; antimicrobial agent; nephrotoxin
cefoperazone Cefoperazone: Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections.. cefoperazone : A semi-synthetic parenteral cephalosporin with a tetrazolyl moiety that confers beta-lactamase resistance.	9.72	31	9	cephalosporin	antibacterial drug
cephalosporin c cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.	3.4	1	1	cephalosporin	fungal metabolite
imipenem, anhydrous Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.	4.35	2	2	beta-lactam antibiotic allergen; carbapenems; zwitterion	antibacterial drug
sulbactam [no description available]	9.72	31	9	penicillanic acids
meropenem Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.	3.86	2	1	alpha,beta-unsaturated monocarboxylic acid; carbapenemcarboxylic acid; organic sulfide; pyrrolidinecarboxamide	antibacterial agent; antibacterial drug; drug allergen
sultamicillin sultamicillin: contains ampicillin & sulbactam	2.71	3	0	penicillanic acid ester
betadex beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.	2.03	1	0	cyclodextrin
fosfomycin Fosfomycin: An antibiotic produced by Streptomyces fradiae.. fosfomycin : A phosphonic acid having an (R,S)-1,2-epoxypropyl group attached to phosphorus.	3.38	1	1	epoxide; phosphonic acids	antimicrobial agent; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
cefepime Cefepime: A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.. cefepime : A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	3.4	1	1	cephalosporin; oxime O-ether	antibacterial drug
cefotaxime Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.	8.37	1	1	1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen

Condition	Relationship Strength	Studies	Trials
Cerebral Intraventricular Haemorrhage [description not available]	2.25	1	0
Infections, Klebsiella [description not available]	3.84	2	1
Klebsiella Infections Infections with bacteria of the genus KLEBSIELLA.	3.84	2	1
Arteriosclerosis, Coronary [description not available]	3	1	0
Pleuropericarditis Inflammation of both the PERICARDIUM and the PLEURA.	3	1	0
Infections, Pseudomonas [description not available]	5	3	1
Acute Disease Disease having a short and relatively severe course.	3.35	2	0
Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.	3	1	0
Pericarditis Inflammation of the PERICARDIUM from various origins, such as infection, neoplasm, autoimmune process, injuries, or drug-induced. Pericarditis usually leads to PERICARDIAL EFFUSION, or CONSTRICTIVE PERICARDITIS.	3	1	0
Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS.	5	3	1
Bacterial Pneumonia [description not available]	2.01	1	0
Health Care Associated Infection [description not available]	2.93	4	0
Benign Neoplasms [description not available]	3.79	2	1
Bacterial Infections, Gram-Negative [description not available]	2.4	2	0
Infection, Postoperative Wound [description not available]	3.79	2	1
Cross Infection Any infection which a patient contracts in a health-care institution.	2.93	4	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.79	2	1
Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.	4.63	3	2
Gram-Negative Bacterial Infections Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.	2.4	2	0
Pneumonia, Bacterial Inflammation of the lung parenchyma that is caused by bacterial infections.	2.01	1	0
Bacterial Disease [description not available]	5.54	6	3
Bacterial Infections Infections by bacteria, general or unspecified.	10.54	6	3
Complication, Postoperative [description not available]	2.02	1	0
Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	2.02	1	0
Breast Cancer [description not available]	1.98	1	0
Infection [description not available]	3.78	2	1
Cancer of Rectum [description not available]	1.98	1	0
Cancer of the Tongue [description not available]	1.98	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	1.98	1	0
Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.	3.78	2	1
Rectal Neoplasms Tumors or cancer of the RECTUM.	1.98	1	0
Tongue Neoplasms Tumors or cancer of the TONGUE.	1.98	1	0
Infection, Wound [description not available]	3.37	1	1
Burns Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.	1.98	1	0
Asthma, Bronchial [description not available]	1.99	1	0
Cancer of Lung [description not available]	1.99	1	0
Centriacinar Emphysema [description not available]	1.99	1	0
Alveolitis, Fibrosing [description not available]	1.99	1	0
Infections, Respiratory [description not available]	2.39	2	0
Pulmonary Consumption [description not available]	1.99	1	0
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	1.99	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	1.99	1	0
Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.	1.99	1	0
Respiratory Tract Diseases Diseases involving the RESPIRATORY SYSTEM.	1.99	1	0
Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.	2.39	2	0
Tuberculosis, Pulmonary MYCOBACTERIUM infections of the lung.	1.99	1	0
Nephritis Inflammation of any part of the KIDNEY.	3.37	1	1
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	3.78	2	1
Bronchitis Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.	3.78	2	1
Pneumonia Infection of the lung often accompanied by inflammation.	3.78	2	1
Empyema, Gall Bladder [description not available]	3.38	1	1
Abscess, Hepatic [description not available]	3.38	1	1
Cholangitis Inflammation of the biliary ductal system (BILE DUCTS); intrahepatic, extrahepatic, or both.	3.38	1	1
Cholecystitis Inflammation of the GALLBLADDER; generally caused by impairment of BILE flow, GALLSTONES in the BILIARY TRACT, infections, or other diseases.	3.38	1	1
Liver Abscess Solitary or multiple collections of PUS within the liver as a result of infection by bacteria, protozoa, or other agents.	3.38	1	1
Blood Diseases [description not available]	3.38	1	1
Hematologic Diseases Disorders of the blood and blood forming tissues.	3.38	1	1
Infections, Staphylococcal [description not available]	2	1	0
Osteomyelitis INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA.	2.41	2	0
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	2	1	0
Hematologic Malignancies [description not available]	2	1	0
Pyrexia [description not available]	2	1	0
Fever An abnormal elevation of body temperature, usually as a result of a pathologic process.	2	1	0
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	2	1	0
Hematologic Neoplasms Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.	2	1	0
Acute Bacterial Prostatitis [description not available]	1.97	1	0
Prostatitis Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.	1.97	1	0

sulperazone

Description

Cross-References

Synonyms (11)

Research Excerpts

Overview

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Research

Studies (31)

Market Indicators

Research Demand Index: 71.32

Study Types

Clinical Trials (10)

Trial Overview

sulperazone

Description

Cross-References

Synonyms (11)

Research Excerpts

Overview

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Research

Studies (31)

Market Indicators

Research Demand Index: 71.32

Study Types

Clinical Trials (10)

Trial Overview

Related Drugs (14)

Related Conditions (67)